FDA Expands Approval of Dysport to Include Treatment of Lower-limb Adult Spasticity

The U.S. Food and Drug Administration has expanded its approval of Dysport (abobotulinumtoxinA) as a  treatment for spasticity in adults from not just the upper limbs but to the lower limbs as well, according to its maker, Ipsen Biopharmaceuticals. Spasticity can affect those with amyotrophic lateral sclerosis (ALS), multiple sclerosis, cerebral…